U.S., Dec. 31 -- ClinicalTrials.gov registry received information related to the study (NCT07310264) titled 'Research Into the Safety of a New Agent (VT-5006) in People With and Without Parkinson's Disease' on Nov. 17.
Brief Summary: This is a first-in-human (FIH) study of orally administered VT-5006 (also known as AX-5006) in healthy adult volunteers (HVs) and adult participants with Parkinson's disease (PD). The goal of this clinical trial is to learn if VT-5006 is safe and tolerable in healthy volunteers and in participants with PD. It has three Parts (A, B, and C).
Part A: Healthy volunteers aged 18-54 will attend a screening visit, take a single dose of VT-5006 or matching placebo after an overnight fast, stay in the clinic for three...